UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-QSB/A
Amendment No. 1
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended June 30, 2006
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT
For the transition period from ________ to __________
Commission File Number: 0-27845
TRANSAX INTERNATIONAL LIMITED
-----------------------------
(Exact name of small business issuer as specified in charter)
COLORADO 84-1304106
-------- ----------
(State or other jurisdiction of (I.R.S. Employer I.D. No.)
incorporation or organization)
8th Floor, 5201 Blue Lagoon Drive
Miami, FL, 33126
---------------------------------
(Address of principal executive offices)
(305) 629-3090
--------------
(Issuer's telephone number, including area code)
Indicate by checkmark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes _____ No __X__
Applicable only to issuers involved in bankruptcy proceedings during the
preceding five years. N/A
Check whether the Registrant filed all documents required to be filed by Section
12, 13 and 15(d) of the Exchange Act after the distribution of securities under
a plan confirmed by a court. Yes _____ No _____
Applicable only to corporate issuers
State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:
Class Outstanding as of August 14, 2006
----- ---------------------------------
Common Stock, $0.00001 par value 31,576,559
EXPLANATORY NOTE REGARDING AMENDMENT NO. 1
Transax International Limited (the "Company") is amending this Quarterly Report
on Form 10-QSB for the period ended June 30, 2006 in response to the U.S.
Securities & Exchange Commission's Comment Letter to the Company dated August
25, 2006 (the "Comment Letter"). In particular, the Company has added language
in the Section entitled "Item 3. Controls & Procedures" in accordance with the
Comment Letter as well as the disclosure of certain negative covenants in the
Section entitled "Item 2 - Management's Discussion & Analysis or Plan of
Operation" with respect to the Securities Purchase Agreement, dated April 1,
2005, by and between the Company and Scott and Heather Grimes. The remaining
Items contained in this report consist of all other Items originally contained
in our Quarterly Report on Form 10-QSB for the period ended June 30, 2006 as
filed on August 14, 2006. This report does not reflect events occurring after
the filing of the original Quarterly Report on Form 10-QSB, nor modify or update
those disclosures in any way other than as required to reflect the comments of
the SEC in the Comment Letter.
TRANSAX INTERNATIONAL LIMITED
FORM 10-QSB
QUARTERLY PERIOD ENDED JUNE 30, 2006
INDEX
Page
----
PART I - FINANCIAL INFORMATION
Item 1 - Consolidated Financial Statements
Consolidated Balance Sheet (Unaudited)
As of June 30, 2006......................................... 3
Consolidated Statements of Operations (Unaudited)
For the Three and Six Months Ended June 30, 2006 and 2005... 4
Consolidated Statements of Cash Flows (Unaudited)
For the Six Months Ended June 30, 2006 and 2005............. 5
Notes to Unaudited Consolidated Financial Statements................. 6-20
Item 2 - Management's Discussion and Analysis or Plan of Operation...21-30
Item 3 - Controls and Procedures.....................................30-31
PART II - OTHER INFORMATION
Item 1 - Legal Proceedings........................................... 32
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds.32-33
Item 3 - Default Upon Senior Securities.............................. 33
Item 4 - Submission of Matters to a Vote of Security Holders......... 33
Item 5 - Other Information........................................... 33
Item 6 - Exhibits.................................................... 33
Signatures........................................................... 33
-2-
TRANSAX INTERNATIONAL LIMITED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
June 30, 2006
(Unaudited)
ASSETS
CURRENT ASSETS:
Cash .......................................................................... $ 482,813
Accounts receivable (net of allowance for doubtful accounts of $0) ............ 399,824
Prepaid expenses and other current assets ..................................... 202,893
------------
TOTAL CURRENT ASSETS ....................................................... 1,085,530
SOFTWARE DEVELOPMENT COSTS, net ................................................. 358,514
PROPERTY AND EQUIPMENT, net ..................................................... 733,359
DEFERRED DEBT OFFERING COSTS .................................................... 14,348
OTHER ASSETS .................................................................... 4,800
------------
TOTAL ASSETS ............................................................... $ 2,196,551
============
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES:
Current portion of loans payable .............................................. $ 261,291
Accounts payable and accrued expenses ......................................... 1,266,771
Due to related parties ........................................................ 229,766
Warrant liability ............................................................. 1,000,783
Convertible feature liability ................................................. 1,830,231
Loan payable - related party .................................................. 147,791
Convertible loan - related party .............................................. 207,035
------------
TOTAL CURRENT LIABILITIES .................................................. 4,943,668
LOANS PAYABLE, NET OF CURRENT PORTION ........................................... 36,828
CONVERTIBLE DEBENTURE PAYABLE, NET .............................................. 156,250
CONVERTIBLE FEATURE LIABILITY ................................................... 268,918
ACCOUNTS PAYABLE AND ACCRUED EXPENSES, NET OF CURRENT PORTION ................... 508,203
------------
TOTAL LIABILITIES .......................................................... 5,913,867
------------
STOCKHOLDERS' DEFICIT:
Series A convertible preferred stock, no par value; 16,000 shares authorized;
16,000 shares issued and outstanding; liquidation preference $1,600,000 ....... 1,478,971
Common stock $.00001 par value; 100,000,000 shares authorized;
31,876,559 shares issued and outstanding ...................................... 318
Paid-in capital ............................................................... 7,865,461
Accumulated deficit ........................................................... (12,872,724)
Deferred compensation ......................................................... (238,332)
Other comprehensive income - Cumulative foreign currency translation adjustment 48,990
------------
TOTAL STOCKHOLDERS' DEFICIT ................................................ (3,717,316)
------------
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT ................................ $ 2,196,551
============
The accompanying notes are an integral part of these unaudited consolidated financial statements
-3-
TRANSAX INTERNATIONAL LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED FOR THE SIX MONTHS ENDED
JUNE 30, JUNE 30,
--------------------------- ---------------------------
2006 2005 2006 2005
------------ ------------ ------------ ------------
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
REVENUES .............................................. $ 1,034,844 $ 861,023 $ 2,015,902 $ 1,501,431
------------ ------------ ------------ ------------
OPERATING EXPENSES:
Cost of product support services .................... 426,864 355,580 818,416 569,976
Compensation and related benefits ................... 220,263 215,571 431,509 384,552
Professional fees ................................... 45,826 58,980 115,546 71,145
Management and consulting fees - related parties .... 116,745 41,250 225,586 74,965
Investor relations .................................. 119,037 790 143,399 15,635
Depreciation and amortization ....................... 56,215 59,027 121,928 103,604
General and administrative .......................... 273,885 185,589 505,410 376,446
------------ ------------ ------------ ------------
TOTAL OPERATING EXPENSES ......................... 1,258,835 916,787 2,361,794 1,596,323
------------ ------------ ------------ ------------
LOSS FROM OPERATIONS .................................. (223,991) (55,764) (345,892) (94,892)
------------ ------------ ------------ ------------
OTHER INCOME (EXPENSES):
Other income (expense) .............................. (26,126) - (48,475) 10,514
Foreign exchange gain (loss) ........................ (6,593) 23,932 (9,468) 26,434
Debt settlement and offering costs .................. - - (153,671) -
Loss from derivative liabilities .................... (935,631) (15,804) (1,184,734) (15,804)
Interest expense .................................... (101,227) (75,617) (233,478) (135,835)
Interest expense - related party .................... (8,691) (43,788) (18,372) (56,277)
------------ ------------ ------------ ------------
TOTAL OTHER EXPENSES ............................. (1,078,268) (111,277) (1,648,198) (170,968)
------------ ------------ ------------ ------------
NET LOSS .............................................. (1,302,259) (167,041) (1,994,090) (265,860)
DEEMED AND CUMULATIVE PREFERRED STOCK DIVIDEND ........ (834,214) - (1,634,214) -
------------ ------------ ------------ ------------
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS .......... $ (2,136,473) $ (167,041) $ (3,628,304) $ (265,860)
============ ============ ============ ============
COMPREHENSIVE LOSS:
NET LOSS ............................................ $ (1,302,259) $ (167,041) $ (1,994,090) $ (265,860)
OTHER COMPREHENSIVE INCOME:
Unrealized foreign currency translation gain (loss) 3,100 (75,051) 34,839 8,874
------------ ------------ ------------ ------------
COMPREHENSIVE LOSS .................................. $ (1,299,159) $ (242,092) $ (1,959,251) $ (256,986)
============ ============ ============ ============
NET LOSS PER COMMON SHARE:
BASIC AND DILUTED ..................................... $ (0.04) $ (0.01) $ (0.06) $ (0.01)
============ ============ ============ ============
WEIGHTED AVERAGE SHARES OUTSTANDING - BASIC AND DILUTED 31,876,559 29,491,294 31,530,852 29,240,092
============ ============ ============ ============
The accompanying notes are an integral part of these unaudited consolidated financial statements
-4-
TRANSAX INTERNATIONAL LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Six Months
Ended June 30,
---------------------------
2006 2005
----------- -----------
(UNAUDITED) (UNAUDITED)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss ....................................................... $(1,994,090) $ (265,860)
Adjustments to reconcile net loss to net cash
provided by (used in) operating activities:
Depreciation and amortization ............................. 121,928 103,604
Amortization of software maintenance costs ................ 104,110 66,524
Beneficial interest ....................................... - 31,250
Stock-based compensation and consulting ................... 117,833 80,041
Grant of warrants in connection with debt extension ....... 46,686 31,200
Foreign exchange gain ..................................... - (18,100)
Amortization of deferred debt issuance costs .............. 116,551 4,783
Amortization of debt discount ............................. 62,500 31,250
Loss from derivative liabilities .......................... 1,184,734 15,804
Changes in assets and liabilities:
Accounts receivable ....................................... (53,182) (199,528)
Prepaid expenses and other current assets ................. (37,764) (49,031)
Other assets .............................................. (2,400) (2,400)
Accounts payable and accrued expenses ..................... (100,579) 379,253
Accrued interest payable, related party ................... 9,495 24,777
Accrued interest payable .................................. - 5,237
Due to related parties .................................... 834 1,191
Accounts payable and accrued expenses - long-term ......... 112,369 11,050
----------- -----------
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES ............ (310,975) 251,045
----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Capitalized software development costs ....................... (137,060) (103,358)
Acquisition of property and equipment ........................ (207,753) (381,046)
----------- -----------
NET CASH USED IN INVESTING ACTIVITIES .......................... (344,813) (484,404)
----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of Series A preferred stock ........... 1,223,734 -
Repayment of advances from related party ..................... - (35,000)
Repayments under capital lease obligations ................... (16,289) (20,962)
Proceeds from convertible debenture .......................... - 336,738
Proceeds from loan payable ................................... 6,614 141,982
Proceeds from loan - related party ........................... (85,000) -
Repayment of loan - related party ............................ - (15,084)
----------- -----------
NET CASH PROVIDED BY FINANCING ACTIVITIES ...................... 1,129,059 407,674
----------- -----------
EFFECT OF EXCHANGE RATE CHANGES ON CASH ........................ 1,667 (114,184)
----------- -----------
NET INCREASE IN CASH ........................................... 474,938 60,131
CASH, BEGINNING OF PERIOD ...................................... 7,875 4,090
----------- -----------
CASH, END OF PERIOD ............................................ $ 482,813 $ 64,221
=========== ===========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest ....................................... $ 95,656 $ 15,084
=========== ===========
Cash paid for income taxes ................................... $ - $ -
=========== ===========
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for debt and accrued interest ............ $ - $ 50,500
=========== ===========
Common stock and options issued for services ................. $ 35,334 $ 101,000
=========== ===========
Loan paid with preferred stock proceeds ..................... $ 255,237 $ -
=========== ===========
Derivative liabilities recorded for deemed preferred
stock dividend .............................................. $ 800,000 $ -
=========== ===========
The accompanying notes are an integral part of these unaudited consolidated financial statements
-5-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 1 - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation
---------------------
The accompanying unaudited consolidated financial statements have been prepared
in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-QSB and Item 310(b)
of Regulation S-B. Accordingly, the financial statements do not include all of
the information and footnotes required by generally accepted accounting
principles for complete financial statements. In the opinion of management, all
adjustments considered necessary to make the interim financials not misleading
have been included and such adjustments are of a normal recurring nature. These
consolidated financial statements should be read in conjunction with the
financial statements for the year ended December 31, 2005 and notes thereto
contained in the Report on Form 10-KSB/A of Transax International Limited ("our
Company" or the "Company") as filed with the Securities and Exchange Commission
(the "Commission"). The results of operations for the six months ended June 30,
2006 are not necessarily indicative of the results for the full fiscal year
ending December 31, 2006.
The consolidated financial statements are prepared in accordance with generally
accepted accounting principles in the United States of America. The consolidated
financial statements include the Company and its wholly-owned subsidiaries,
Transax Limited, Medlink Conectividade em Saude Ltda ("Medlink") (formerly TDS
Telecommunication Data Systems Ltda.), Transax (Australia) Pty Ltd., and Medlink
Technologies, Inc. All material intercompany balances and transactions have been
eliminated in the consolidated financial statements.
Organization
------------
Transax International Limited was incorporated in the State of Colorado in 1999.
The Company, primarily through its wholly-owned subsidiary, Medlink
Conectividade em Saude Ltda ("Medlink") (formerly TDS Telecommunication Data
Systems Ltda. through April 4, 2006), is an international provider of
information network solutions specifically designed for healthcare providers and
health insurance companies. The Company's MedLink Solution (TM) enables the real
time automation of routine patient eligibility, verification, authorizations,
claims processing and payment functions. The Company has offices located in
Miami, Florida and Rio de Janeiro, Brazil.
Use of estimates
----------------
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the dates of the financial statements and
the reported amounts of revenues and expenses during the reporting periods.
Actual results could differ from those estimates. Estimates used in the
preparation of the accompanying financial statements include the allowance for
doubtful accounts receivable, the useful lives of property, equipment and
software development costs, variables used to determine stock-based
compensation, and the valuation of derivative liabilities.
-6-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 1 - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(CONTINUED)
Fair Value of Financial Instruments
-----------------------------------
The fair value of our cash and cash equivalents, accounts receivable, accounts
payable and accrued expenses approximate carrying values due to their short
maturities. The fair values of our debt instruments approximate their carrying
values based on rates currently available to us.
Concentrations of Credit Risk
-----------------------------
Financial instruments that potentially subject us to significant concentrations
of credit risk consist principally of cash and accounts receivable.
The Company performs certain credit evaluation procedures and does not require
collateral for financial instruments subject to credit risk. The Company
believes that credit risk is limited because the Company routinely assesses the
financial strength of its customers, and based, upon factors surrounding the
credit risk of its customers, establishes an allowance for uncollectible
accounts and, as a consequence, believes that its accounts receivable credit
risk exposure beyond such allowances is limited.
Revenue recognition
-------------------
The Company's revenues, which do not require any significant production,
modification or customization for the Company's targeted customers and do not
have multiple elements, is recognized when (1) persuasive evidence of an
arrangement exists; (2) delivery has occurred; (3) the Company's fee is fixed
and determinable, and; (4) collectibility is probable.
Substantially all of the Company's revenues are derived from the processing of
applications by healthcare providers for approval of patients for healthcare
services from insurance carriers. The Company's software or hardware devices
containing the Company's software are installed at the healthcare provider's
location. The Company offers transaction services to authorize and adjudicate
identity of the patient and obtains "real time" approval for any necessary
medical procedure from the insurance carrier. The Company's transaction-based
solutions provide remote access for healthcare providers to connect with
contracted insurance carriers. Transaction services are provided through
contracts with insurance carriers and others, which specify the services to be
utilized and the markets to be served. The Company's clients are charged for
these services on a per transaction basis. Pricing varies depending type of
transactions being processed under the terms of the contract for which services
are provided. Transaction revenues are recognized in the period in which the
transactions are performed.
Comprehensive Loss
------------------
Other comprehensive loss currently includes only foreign currency translation
adjustments.
-7-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 1 - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(CONTINUED)
Foreign Currency Translation
----------------------------
The assets and liabilities of the Company's foreign subsidiaries are translated
into U.S. dollars at the year-end exchange rates, equity is converted
historically and all revenue and expenses are translated into U.S. dollars at
the average exchange rates prevailing during the periods in which these items
arise. Translation gains and losses are deferred and accumulated as a component
of other comprehensive income or loss in stockholders' deficit. Transaction
gains and losses that arise from exchange rate fluctuations on transactions
denominated in a currency other than the functional currency (Medlink -
Brazilian Real, Transax Australia, - Australian dollar and Transax and the
Company - USD) are included in the Statement of Operations as incurred.
Stock-based compensation
------------------------
Effective January 1, 2006, the Company adopted Statement of Financial Accounting
Standards No. 123R (revised 2004), Share Based Payment ("SFAS No. 123R"). SFAS
No. 123R establishes the financial accounting and reporting standards for
stock-based compensation plans. As required by SFAS No. 123R, the Company
recognizes the cost resulting from all stock-based payment transactions
including shares issued under its stock option plans in the financial
statements. The recognition of this cost will be made on the modified
prospective basis, which applies to new stock-based awards issued after December
31, 2005, and for awards modified, purchased or cancelled after that date.
Prior to January 1, 2006, the Company accounted for stock-based employee
compensation plans (including shares issued under its stock option plans) in
accordance with APB Opinion No. 25 and followed the pro forma net income, pro
forma income per share, and stock-based compensation plan disclosure
requirements set forth in the Statement of Financial Accounting Standards No.
123, Accounting for Stock-Based Compensation ("SFAS No. 123"). Had compensation
cost for the stock option plan been determined based on the fair value of the
options at the grant dates consistent with the method of SFAS 123, "Accounting
for Stock Based Compensation", the Company's net income and income per share
would have been changed to the pro forma amounts indicated below for the six
months ended June 30, 2005:
Six months ended
June 30, 2005
----------------
Net loss as reported ...................... $(265,860)
Less: total stock-based employee
compensation expense determined under
fair value based method, net of related tax
effect .................................... (50,871)
---------
Pro forma net loss ........................ $(316,731)
=========
Basic and diluted loss per share:
As reported ......................... $ (.01)
=========
Pro forma ........................... $ (.01)
=========
The option grants are estimated as of the date of grant using the Black-Scholes
option-pricing model with the following assumptions used for grants as of June
30, 2005: expected volatility of 205%; risk free interest rate of 3.25%;
expected life of 5 years and annual dividend rate of 0%.
-8-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 1 - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(CONTINUED)
Loss per common share
---------------------
Basic loss per share is computed by dividing net loss by the weighted average
number of shares of common stock outstanding during the period. Diluted income
per share is computed by dividing net income by the weighted average number of
shares of common stock, common stock equivalents and potentially dilutive
securities outstanding during each period. Diluted loss per common share is not
presented because it is anti-dilutive, although the common stock equivalents may
dilute earnings in the future. The Company's common stock equivalents at June
30, 2006 include the following:
Options ........................................ 3,425,000
Warrants ....................................... 16,902,500
Preferred stock ................................ 10,204,082
Convertible loans payable - related party ...... 1,400,000
Debenture payable .............................. 1,644,737
----------
Total ..................................... 33,576,319
==========
Concentrations of Credit Risk
-----------------------------
Financial instruments that potentially subject us to significant concentrations
of credit risk consist principally of cash and accounts receivable.
The Company performs certain credit evaluation procedures and does not require
collateral for financial instruments subject to credit risk. The Company
believes that credit risk is limited because the Company routinely assesses the
financial strength of its customers, and, based upon factors surrounding the
credit risk of its customers, establishes an allowance for uncollectible
accounts and, as a consequence, believes that its accounts receivable credit
risk exposure beyond such allowances is limited. The Company recognizes an
allowance for doubtful accounts to ensure accounts receivable are not overstated
due to uncollectibility and are maintained for all customers based on a variety
of factors, including the length of time the receivables are past due,
significant one-time events and historical experience. An additional reserve for
individual accounts is recorded when the Company becomes aware of a customer's
inability to meet its financial obligation, such as in the case of bankruptcy
filings or deterioration in the customer's operating results or financial
position. If circumstances related to customers change, estimates of the
recoverability of receivables would be further adjusted. As of June 30, 2006,
the allowance for doubtful accounts was $0.
The Company's principal business activities are located in Brazil. Although
Brazil is considered to be economically stable, it is always possible that
unanticipated events in foreign countries could disrupt the Company's
operations.
The Company had net revenues to two major customers during each of the six month
periods ended June 30, 2006 and 2005. These revenues accounted for approximately
91%, or $1,844,500 and 94% or $1,414,000 of the total revenues for the six
months ended June 30, 2006 and 2005, respectively. For the six months ended June
30, 2006, these two major customers accounted for 52% and 39% of net revenues,
respectively. At June 30, 2006, these two major customers accounted for 52% and
39%, respectively, of the total accounts receivable balance outstanding.
-9-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 1 - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(CONTINUED)
Concentrations of Credit Risk (continued)
-----------------------------------------
The Company maintains its cash in accounts with major financial institutions in
the United States, Australia and Brazil in the form of demand deposits and money
market accounts. Deposits in these banks may exceed the amounts of insurance
provided on such deposits. As of June 30, 2006, the Company had no deposits
subjected to such risk. We have not experienced any losses on our deposits of
cash and cash equivalents.
Accounting for Conversion Features and Warrants Issued with Preferred Stock
---------------------------------------------------------------------------
The Company issued $1,600,000 of convertible series A preferred stock, which
contained an Embedded Conversion Feature ("ECF") and warrants to purchase common
stock. In accordance with the guidance in paragraph 12 of Statement of Financial
Accounting Standards ("SFAS") No. 133, "Accounting for Derivative Instruments
and Hedging Activities," it was necessary to evaluate separation of the
conversion option from the debt host and account for it separately as a
derivative if the conversion option met certain criteria. The Conversion option
met all three criteria of paragraph 12: (1) the conversion feature is not
clearly and closely related to the host component, (2) the convertible
instrument is not accounted for at fair value, and (3) the embedded conversion
option meets the definition of a derivative in paragraph 6 of SFAS No. 133.
To assess whether or not the ECF would be classified as stockholders' equity if
it were freestanding, management considered the guidance in EITF 00-19,
"Accounting for Derivative Financial Instruments Indexed to, and Potentially
Settled in, a Company's Own Stock." In assessing whether or not the conversion
option would be classified as equity or a liability if it were freestanding,
management determined whether or not the series A convertible preferred stock is
considered "conventional." EITF 00-19 and EITF 05-2, "The Meaning of
Conventional Convertible Debt Instruments in issue No. 00-19," defines
conventional convertible debt as debt whereby the holder will, at the issuer's
option, receive a fixed amount of shares or the equivalent amount of cash as
proceeds when he exercises the conversion option. Management determined that
series A convertible preferred stock was not "conventional," and the Company
considered all aspects of EITF 00-19, paragraphs 12-33.
This caused the ECF of the series A convertible preferred stock to be classified
as a derivative financial instrument under SFAS No. 133. In addition, all
warrants to purchase common stock issued with the preferred stock were then
deemed to be classified as derivative instruments under SFAS No. 133. The
accounting treatment of derivative financial instruments requires that the
Company record the ECF and warrants at their fair values as of each reporting
date. Any change in fair value is recorded as non-operating, non-cash income or
expense at each reporting date. The derivatives were valued using the
Black-Scholes option pricing model and are classified in the consolidated
balance sheet as current liabilities at June 30, 2006.
Reclassifications
-----------------
Certain prior periods' balances have been reclassified to conform to the current
period's financial statement presentation. These reclassifications had no impact
on previously reported financial position, results of operations or cash flows.
-10-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 1 - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(CONTINUED)
Recent accounting pronouncements
--------------------------------
In February 2006, the Financial Accounting Standards Board ("FASB") issued SFAS
No. 155, "Accounting for Certain Hybrid Financial Instruments - an amendment of
FASB Statements No. 133 and 140" ("SFAS 155"). SFAS 155 permits fair value
re-measurement for any hybrid financial instrument that contains an embedded
derivative that otherwise would require bifurcation and clarifies which
interest-only strips and principal-only strips are not subject to the
requirements of Statement 133. SFAS 155 establishes a requirement to evaluate
interests in securitized financial assets to identify interests that are
freestanding derivatives or that are hybrid financial instruments that contain
an embedded derivative requiring bifurcation and clarifies that concentrations
of credit risk in the form of subordination are not embedded derivatives.
Lastly, SFAS 155 amends SFAS 140 to eliminate the prohibition on a qualifying
special-purpose entity from holding a derivative financial instrument that
pertains to a beneficial interest other than another derivative financial
instrument. SFAS 155 is effective in the first fiscal year that begins after
September 15, 2006. The Company is still assessing the impact, if any, on its
consolidated financial position, results of operations and cash flows.
NOTE 2 - RELATED PARTY TRANSACTIONS
Convertible Loans Payable
-------------------------
At June 30, 2006, the Company had aggregate loans payable for $175,000 to a
related party whose officer is an officer of the Company. On March 23, 2005, the
Company modified the terms of its convertible loans to this related party. Under
the modified terms, $75,000 of principal due under the convertible loans is due
on March 31, 2007 and is convertible into the Company's common stock at $.125
per share. The remaining principal of $100,000 is due on April 30, 2007 and is
convertible into the Company's common stock at $.125 per share. For each common
share received upon conversion of the principal balance, the related party is
entitled to receive one warrant to purchase the Company's common stock at $.25
per share for a period of two years from the conversion date. The interest rate
of the loan is 12% per annum compounded monthly. At June 30, 2006, interest due
on these two loans amounted to $32,035 and the aggregate principal amount due is
$175,000. During the six months ended June 30, 2006 and 2005, the Company
incurred $10,414 and $17,852, respectively, in interest expense related to these
two loans. In the 2005 period, the Company did not incur beneficial conversion
charges on these convertible loans because the conversion price was equivalent
to the average offering price for equity when these loans became convertible.
Due to Related Parties
----------------------
For the six months ended June 30, 2006 and 2005, the Company incurred $86,250
and $82,500 in management fees to an officer/director of the Company,
respectively. Effective April 2006, the Company's board of directors agreed to
increase the compensation of this officer/director from $13,750 per month to
$15,000 per month. At June 30, 2006, $209,869 in management fees and other
expenses was outstanding to this officer/director and is included in due to
related parties on the accompanying balance sheet. The amounts due is unsecured,
non-interest bearing and is payable on demand.
For the six months ended June 30, 2006, the Company incurred $25,902 in
accounting fees to a company whose officer is an officer of the Company. At June
30, 2006, $12,552 in these fees was outstanding to this officer and is included
in due to related parties on the accompanying balance sheet. The amount due is
unsecured, non-interest bearing and is payable on demand.
-11-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 2 - RELATED PARTY TRANSACTIONS (CONTINUED)
Due to Related Parties (continued)
----------------------------------
For the six months ended June 30, 2006, the Company incurred $40,600 in
consulting fees to an officer of the Company. At June 30, 2006, $7,345 in these
fees was outstanding to this officer and is included in due to related parties
on the accompanying balance sheet. The amount due is unsecured, non-interest
bearing and is payable on demand. Additionally, the Company granted this officer
100,000 options to purchase 100,000 shares of the Company's common stock at
$0.15 per share. The options expire on February 5, 2011. The fair value of this
option grant was estimated at $12,834 on the date of grant using the
Black-Scholes option-pricing model. In connection with these options, the
Company recorded stock-based compensation expense of $12,834, which has been
included in management and consulting fees - related party on the accompanying
consolidated statement of operations (See note 4).
For the six months ended June 30, 2006, the Company incurred $60,000 in
consulting fees to a director of the Company.
Loan Payable - Related Party
----------------------------
On March 5, 2004, the Company borrowed Euro 115,000 ($144,366 at June 30, 2006)
from an officer of the Company for working capital purposes. The loan accrues
0.8% interest compounded monthly, had an initial term of twelve months, and is
repayable quarterly in arrears. The officer agreed to extend this loan for an
additional twelve months until March 2006. The due date of this loan is
currently being negotiated and is payable on demand. Additionally, during 2005,
the Company borrowed $85,000 from this officer, which was repaid in 2006. This
loan accrued interest at 9.6% per annum. For the six months ended June 30, 2006
and 2005, the Company incurred $7,330 and $7,425, respectively, in interest
related to these loans. At June 30, 2006, $3,455 in interest was accrued on
these loans and the aggregate principal and interest amount due is $144,336 and
is included in loan payable - related party on the accompanying balance sheet.
NOTE 3 - FINANCING ARRANGEMENTS
Loan Payable
------------
On October 25, 2004, the Company and Cornell Capital Partners ("Cornell")
entered into a Securities Purchase Agreement, pursuant to which Cornell
purchased two 5% secured convertible debentures. The initial convertible
debenture in the original principal amount of $125,000 was dated October 25,
2004 and the second convertible debenture in the original principal amount of
$125,000 was dated January 4, 2005 (collectively, the "Original Debentures"). In
connection with the terms of the original debentures, for the six months ended
June 30, 2005, the Company recorded a beneficial conversion amount of $31,250 as
interest expense since the debentures were immediately convertible.
On May 17, 2005, the Company and Cornell entered into a $255,237 Promissory Note
(the "Note"), whereby the Original Debentures were terminated. This Note
represents the outstanding principal balance of $250,000 on the Original
Debentures, plus accrued but unpaid interest through April 30, 2005 equal to
$5,237. In January 2006, in connection with a preferred stock offering, this
note was repaid.
The Company's subsidiary, Medlink, has several loans and credit lines with
financial institutions. The loans require monthly installments, bear interest at
rates ranging from 30% to 50% per annum, are secured by certain receivables and
assets of Medlink, and are due through November 2007. At June 30, 2006, loans
payable to these financial institutions aggregated $298,119.
-12-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 3 - FINANCING ARRANGEMENTS (CONTINUED)
Convertible Debenture Payable
-----------------------------
On April 1, 2005, the Company entered into a Securities Purchase Agreement with
Scott and Heather Grimes, Joint Tenants - with Rights of Survivorship (the
"Investor"). Pursuant to the Securities Purchase Agreement, the Company issued
convertible debentures to the Investor in the original principal amount of
$250,000. The debentures are convertible at the holder's option any time up to
maturity at a conversion price equal to the lower of (i) 120% of the closing bid
price of the common stock on the date of the debentures or (ii) 80% of the
lowest closing bid price of the common stock for the five trading days
immediately preceding the conversion date. The debentures have a two-year term
and accrue interest at 5% per year. At maturity, the debentures will
automatically convert into shares of common stock at a conversion price equal to
the lower of (i) 120% of the closing bid price of the common stock on the date
of the debentures or (ii) 80% of the lowest closing bid price of the common
stock for five trading days immediately preceding the conversion date.
The Company determined that the conversion feature of the convertible debentures
represents an embedded derivative since the debentures are convertible into a
variable number of shares upon conversion. Accordingly, the convertible
debentures are not considered to be conventional debt under EITF 00-19 and the
embedded conversion feature must be bifurcated from the debt host and accounted
for as a derivative liability. The Company believes that the aforementioned
embedded derivative meets the criteria of SFAS 133 and EITF 00-19, and should be
accounted for as separate derivative with a corresponding value recorded as a
liability. Accordingly, the fair value of this derivative instrument has been
recorded as a liability on the consolidated balance sheet with the corresponding
amount recorded as a discount to the debentures. Such discount will be accreted
from the date of issuance to the maturity date of the debentures. The change in
the fair value of the liability for derivative contracts will be credited to
other income/(expense) in the consolidated statements of operations. On February
1, 2006, the Company and the debenture holder mutually agreed to extend the term
of the debentures until December 1, 2007. In addition, the Company granted a
warrant to purchase 400,000 shares of the Company's common stock to the
debenture holder. The warrant has a term of 2 years and is exercisable at $0.20
per share. The fair value of this warrant grant was estimated at $46,686 on the
date of grant using the Black-Scholes option-pricing model. In connection with
these warrants, on February 1, 2006, the Company initially recorded debt
settlement expense of $46,686 and a warrant liability of $46,686. At the end of
each reporting period, the Company revalues the warrant and convertible feature
derivative liabilities. For the six months ended June 30, 2006, after
adjustment, the Company recorded a loss on valuation of the derivative liability
of $19,022. Amortization of debt discount for the six months ended June 30, 2006
was $62,500 and is included in interest expense. Amortization of debt offering
costs for the six months ended June 30, 2006 was $9,566 and is included in
interest expense. At June 30, 2006, the estimated fair values of the convertible
feature derivative liabilities and warrants were $268,918 and $65,302,
respectively, and are reflected as liabilities on the accompanying consolidated
balance sheet.
The Company agreed to register, on a best efforts basis, 3,571,429 shares of its
common stock underlying the conversion of the Debentures and the exercise of the
warrant not later than 30 days after the Company files its annual report on Form
10-KSB for the fiscal year ended December 31, 2005.
The convertible debenture liability is as follows at June 30, 2006:
Convertible debentures payable .................. $ 250,000
Less: unamortized discount on debentures ........ (93,750)
---------
Convertible debentures, net ..................... $ 156,250
=========
-13-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 3 - FINANCING ARRANGEMENTS (CONTINUED)
Standby Equity Distribution Agreement
-------------------------------------
On October 25, 2004, the Company entered into a Standby Equity Distribution
Agreement with Cornell. Pursuant to the Standby Equity Distribution Agreement,
the Company could, at its discretion, periodically sell to Cornell shares of
common stock for a total purchase price of up to $5.0 million. On May 17, 2005,
the Company entered into a Termination Agreement with Cornell, whereby the
Standby Equity Distribution Agreement, dated October 25, 2004, and the related
Registration Rights Agreement, Placement Agent Agreement and Escrow Agreement
were terminated.
Upon execution of the Termination Agreement, the Company entered into a new
Standby Equity Distribution Agreement with Cornell on May 17, 2005. On January
13, 2006, the Company entered into a Termination Agreement with Cornell (the
"SEDA Termination Agreement") pursuant to which the Parties terminated the
Standby Equity Distribution Agreement, the Registration Rights Agreement and the
Placement Agent Agreement, each dated as of May 17, 2005. In connection with the
Standby Equity Distribution Agreement, in December 2004, the Company issued to
Cornell 1,202,779 shares of the Company's Common Stock (the "Investor's Shares")
and in connection with the Placement Agent Agreement, the Company issued to
Monitor Capital, Inc., as Placement Agent, 125,000 shares of the Company's
Common Stock (the "Placement Agent's Shares").
In December 2004, the Company valued the common shares issued to Cornell at the
fair market value on the dates of grant of $0.1664 per share, or $200,000, based
on the quoted trading price for the stock. At December 31, 2005, the commitment
fee was deemed to be a deferred offering cost on the accompanying balance sheet.
Pursuant to the SEDA Termination Agreement, Cornell shall retain 600,889 of the
Investor's Shares and return the other 601,890 of the Investor's Shares to the
Company to be cancelled. Monitor Capital, Inc. shall retain 62,500 of the
Placement Agent's Shares and return the other 62,500 of the Placement's Agent's
Shares to the Company to be cancelled. In connection with the termination of the
SEDA, the Company received and cancelled 664,390 shares of its common stock with
a fair market value of $93,015 and for the six months ended June 30, 2006,
recorded debt offering cost expense of $106,985 on the accompanying consolidated
statement of operations.
NOTE 4 - STOCKHOLDERS' DEFICIT
Preferred Stock
---------------
On January 13, 2006, the Company's Board of Directors approved the creation of
16,000 shares of Series A Convertible Preferred Stock having the following
rights, preferences and limitations:
(a) each share has a stated value of $100 per share and no par value;
(b) With respect to the payment of dividends and other distributions on the
capital stock of the Company, including distribution of the assets of
the Company upon liquidation, the Series A Preferred Shares shall be
senior to the common stock of the Company, par value $.00001 per share
and senior to all other series of Preferred Shares (the "Junior
Stock").
-14-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 4 - STOCKHOLDERS' DEFICIT (CONTINUED)
Preferred Stock (continued)
---------------------------
(c) The holders of Series A Preferred Shares shall be entitled to receive
dividends or distributions on a pro rata basis according to their
holdings of shares of Series A Preferred Shares in the amount of seven
percent (7%) per year (computed on the basis of a 365-day year and the
actual days elapsed). Dividends shall be paid in cash. Dividends shall
be cumulative. No cash dividends or distributions shall be declared or
paid or set apart for payment on the Common Stock in any calendar year
unless cash dividends or distributions on the Series A Preferred Shares
for such calendar year are likewise declared and paid or set apart for
payment. No declared and unpaid dividends shall bear or accrue
interest.
(d) Each share of Series A Preferred Shares shall be convertible, at the
option of the holder thereof, at any time after the date of issuance of
such shares, into such number of fully paid and non-assessable shares
of Common Stock equal to the sum of (i) the Liquidation Amount of the
Series A Preferred Shares plus (ii) all accrued but unpaid dividends
thereon, divided by the Conversion Price, as defined. The Conversion
Price" shall be equal to the lower of (i) $0.192 ( the "Fixed
Conversion Price"), or (ii) eighty percent (80%) of the lowest daily
volume weighted average price ("VWAP") of the Common Stock during the
ten (10) Trading Days immediately preceding the date of conversion (the
"Market Conversion Price"). The VWAP shall be determined using price
quotations from Bloomberg, LP. "Trading Day" shall mean any day during
which the Nasdaq OTC Bulletin Board shall be open for trading.
Additionally, each share of Series A Preferred Shares shall
automatically convert into shares of Common Stock at the Conversion
Price then in effect immediately upon the consummation of the
occurrence of a stock acquisition, merger, consolidation or
reorganization of the Company into or with another entity through one
or a series of related transactions, or the sale, transfer or lease of
all or substantially all of the assets of the Company. Each share of
Series A Preferred Shares shall automatically convert into shares of
Common Stock at the Conversion Price then in effect immediately upon
the third anniversary of the date of Investment Agreement.
(e) The Series A Preferred Shares shall not have any voting rights except
as provided under the laws of the state of Colorado.
(f) The shares are not subject to redemption. However, the Company, at its
option, shall have the right to redeem (unless otherwise prevented by
law), with three (3) business days advance written notice (the
"Redemption Notice"), any shares of Series A Preferred Shares provided
that the closing bid price of the of the Company's Common Stock, as
reported by Bloomberg, LP, is less than the Fixed Conversion Price at
the time of the Redemption Notice. The Company shall pay an amount
equal to One Hundred Fifteen percent (115%) of the Liquidation Amount,
plus accrued but unpaid dividends thereon (the "Redemption Amount").
The Company shall deliver to the holder the Redemption Amount on the
third (3rd) business day after the Redemption Notice. After receipt of
a Redemption Notice, the holder shall be entitled to continue to
convert outstanding shares of Series A Preferred Shares until the
Redemption Price is received, subject to the conversion limitations as
defined.
-15-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 4 - STOCKHOLDERS' DEFICIT (CONTINUED)
Preferred Stock (continued)
---------------------------
On January 13, 2006, the Company entered into an Investment Agreement with
Cornell and, together with the Company, (the "Parties"), pursuant to which the
Company shall sell to Cornell up to 16,000 shares of Series A Convertible
Preferred Stock, no par value per share, (the "Series A Preferred Shares") which
shall be convertible, at Cornell's discretion, into shares of the Company's
common stock, par value $.00001 per share (the "Common Stock") for a total price
of up to $1,600,000.
Of the 16,000 Series A Preferred Shares to be sold to Cornell, 8,000 Series A
Preferred Shares were sold to Cornell on January 13, 2006 and had a purchase
price of $800,000, which consisted of $255,237 from the surrender of a
Promissory Note (as described below) and $544,763 consisting of new funding,
from which the Company received net proceeds of $470,734 after the payment of
placement fees and expenses of $74,029. On May 8, 2006, the Company sold the
remaining 8,000 shares of Series A Preferred Shares to Cornell, at the purchase
price of $800,000 and received net proceeds of $728,000 (net of placement fees
of $72,000).
In connection with the sale of the Series A Preferred Shares, on January 13,
2006, the Parties agreed that Cornell would surrender the Promissory Note issued
by the Company to Cornell on May 17, 2005, in the principal amount of $255,237,
in exchange for $255,237 of Series A Preferred Shares. As of January 13, 2006,
the full amount outstanding under the Promissory Note was $255,237, plus accrued
and unpaid interest of $0. As a result of the Parties' agreement, the Promissory
Note was retired and canceled. The Parties also agreed to terminate the
Securities Purchase Agreement and the Investor Registration Rights Agreement,
each dated as of October 25, 2004, as well as the Pledge and Escrow Agreements,
each dated as of October 21, 2004, that were entered into by the Parties in
connection with the issuance of the Promissory Note.
On January 13, 2006, the Company also issued to Cornell warrants to purchase up
to 5,000,000 shares of Common stock. The first warrant issued to Cornell for
2,500,000 shares of Common Stock at an exercise price of $0.30 per share, shall
terminate after the five (5) year anniversary of the date of issuance. The
second warrant issued to Cornell was for 2,500,000 shares of Common Stock at an
exercise price of $0.20 per share, and shall terminate after the five (5) year
anniversary of the date of issuance.
Subject to the terms and conditions of an Investor Registration Rights
Agreement, the Company was required to prepare and file, no later than the
earlier of 30 days from the date the Company files its Form 10-KSB for the year
ended December 31, 2005 or the date that such filing is due (the "Scheduled
Filing Deadline"), with the SEC, a registration statement on Form S-1 or SB-2
under the 1933 Act (the "Initial Registration Statement") for the registration
for the resale by the Investor of the underlying common stock and warrants,
including at least 25,000,000 shares underlying the Series A Preferred Shares
and 5,000,000 Warrant Shares. The Company shall cause the Registration Statement
to remain effective until all of the Registerable Securities have been sold. The
Company shall use its best efforts (i) to have the Initial Registration
Statement declared effective by the SEC no later than ninety (90) days from the
date hereof (the "Scheduled Effective Deadline") and (ii) to insure that the
Initial Registration Statement and any subsequent Registration Statement remains
in effect until all of the Registerable Securities have been sold, subject to
the terms and conditions of this Agreement. It shall be an event of default
hereunder if the Initial Registration Statement is not declared effective by the
SEC within one hundred twenty (120) days (July 29, 2006). The Company filed its
initial registration statement on Form SB-2 on May 9, 2006.
In the event the Registration Statement is not declared effective by the SEC on
or before the Scheduled Effective Deadline, or if after the Registration
Statement has been declared effective by the SEC, sales cannot be made pursuant
to the Registration Statement, the Company will pay as liquidated damages (the
-16-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 4 - STOCKHOLDERS' DEFICIT (CONTINUED)
Preferred Stock (continued)
---------------------------
"Liquidated Damages") to the holder, at the holder's option, either a cash
amount or shares of the Company's Common Stock equal to two percent (2%) of the
Liquidation Amount (as defined in the Certificate of Designation of Series A
Convertible Preferred Shares) outstanding as Liquidated Damages for each thirty
(30) day period or any part thereof after the Scheduled Filing Deadline or the
Scheduled Effective Deadline as the case may be.
In accordance with SFAS No. 133, the Company is required to record the fair
value of the ECF and warrants as a liability. In connection with the initial
sale of the Series A Preferred Stock, the initial estimated fair value of the
ECF and warrants was $588,363 and $689,000, respectively, which reduced the
carrying value of the Series A Preferred Stock to zero. The $477,363 excess
value of the fair values of the ECF and warrants over the gross proceeds
received from the Preferred Stock was charged to other expense upon recording.
The initial fair values of the ECF and warrants were estimated using the
Black-Scholes option pricing model with the following assumptions: estimated
volatility of 222%; risk-free interest rate of 4.26%; estimated life of 5 years
and no dividends. In connection with the final sale of the Series A Preferred
Stock on May 8, 2006, the initial estimated fair value of the ECF was
$1,003,135, which reduced the carrying value of the Series A Preferred Stock to
zero. The $203,135 excess value of the fair values of the ECF over the gross
proceeds received from the Preferred Stock was charged to other expense upon
recording. The initial fair value of this ECF was estimated using the
Black-Scholes option pricing model with the following assumptions: estimated
volatility of 228%; risk-free interest rate of 5.13%; estimated life of 2.7
years and no dividends. At June 30, 2006, the Company revalued the EFC and
warrants resulting in an additional loss on derivative liability of $485,214 due
to an increase in the Company's stock price. At June 30, 2006, the fair value of
the ECF and warrants were estimated using the Black-Scholes option pricing model
with the following assumptions: estimated volatility of 228%; risk-free interest
rate of 5.16%; estimated life of 1.5 to 4.55 years and no dividends. At June 30,
2006, the estimated fair value of the ECF and warrants was $1,830,231 and
$935,481, respectively, and are reflected as derivative liabilities on the
accompanying consolidated balance sheet.
At June 30, 2006, cumulative and unpaid Series A preferred dividends amounted to
$34,214 and are in included in accounts payable and accrued expenses on the
accompanying consolidated balance sheet.
Common Stock
------------
In connection with the termination of the SEDA, the Company received and
cancelled 664,390 shares of its common stock with a fair market value of
$93,015.
On March 20, 2006, the Company entered into a one-year consulting contract for
business development services. In connection with the agreement, the Company
issued 900,000 shares of common stock. The Company valued these common shares at
the fair market value on the dates of grant or $0.12 per share based on the
quoted trading price and recorded deferred consulting expense of $108,000 to be
amortized over the service period. In addition, the Company granted a warrant to
purchase 2,000,000 shares of the Company's common stock. The warrant has a term
expiring January 31, 2009. 1,000,000 of the warrants are exercisable at $0.20
per share and 1,000,000 of the warrants are exercisable at $0.25 per share. The
fair value of this warrant grant was estimated at $221,998 or $.11 per warrant
on the date of grant using the Black-Scholes option-pricing model. In connection
with these warrants, the Company recorded deferred consulting expense, which
will be amortized over the contract period. For the six months ended June 30,
2006, the Company recorded consulting expense of $91,666 in connection with the
issuance of these common shares and warrants.
-17-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 4 - STOCKHOLDERS' DEFICIT (CONTINUED)
Stock Options
-------------
On January 26, 2006, the Company's Board of Directors, pursuant to written
unanimous consent, appointed David Sasso as the Vice President of Investor
Relations and Corporate Communications of the Company effective January 26,
2006. On January 26, 2006, the Company granted Mr. Sasso 100,000 options to
purchase 100,000 shares of the Company's common stock at $0.15 per share. The
options expire on February 5, 2011. The fair value of this option grant was
estimated at $12,834 on the date of grant using the Black-Scholes option-pricing
model. In connection with these options, the Company recorded stock-based
compensation expense of $12,834, which has been included in management and
consulting fees - related party on the accompanying consolidated statement of
operations.
On February 5, 2006, the Company granted options to purchase 100,000 shares of
common stock to a consultant for business development services rendered. The
options are exercisable at $0.15 per share and expire on February 5, 2011. The
fair value of this option grant was estimated at $13,333 on the date of grant
using the Black-Scholes option-pricing model. In connection with these options,
the Company recorded consulting expense of $13,333.
A summary of the status of the Company's outstanding stock options as of June
30, 2006 and changes during the period then ended are as follows:
Number of Weighted Average
Options Exercise Price
--------- ----------------
Balance at December 31, 2005 ......... 3,225,000 $ 0.31
Granted .............................. 200,000 0.15
Exercised ............................ - -
Forfeited ............................ - -
--------- ------
Balance at June 30, 2006 ............. 3,425,000 $ 0.30
========= ======
Options exercisable at end of period 3,425,000 $ 0.30
========= ======
Weighted average fair value of options
granted during the period ............ $ 0.15
The following table summarizes information about employee and consultants stock
options outstanding at June 30, 2006:
Options Outstanding Options Exercisable
--------------------------------------------------- -------------------------
Weighted
Average Weighted Weighted
Range of Number Remaining Average Number Average
Exercise Outstanding at Contractual Exercise Exercisable at Exercise
Price June 30, 2006 Life (Years) Price June 30, 2006 Price
-------- -------------- ------------ -------- -------------- --------
$ 0.50 1,425,000 2.12 $ 0.50 1,425,000 $ 0.50
$ 0.20 600,000 3.50 0.20 600,000 0.20
$ 0.15 1,400,000 4.16 0.15 1,400,000 0.15
-------------- -------- -------------- --------
3,425,000 $ 0.30 3,425,000 $ 0.30
============== ======== ============== ========
As of June 30, 2006, there are no unrecognized compensation costs since all
options granted under the stock option plans are completely vested.
-18-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 4 - STOCKHOLDERS' DEFICIT (CONTINUED)
Stock Options (continued)
-------------------------
The valuation of the option grants is estimated as of the date of grant using
the Black-Scholes option-pricing model with the following assumptions used for
grants during the six months ended June 30, 2006: expected volatility of 222%;
risk free interest rate ranging from 3.75% to 4.26%; expected life of 5 years
and annual dividend rate of 0%.
In utilizing the Black-Scholes, the Company calculates volatility using the
historical volatility of our stock, the expected term is based on our estimate
of when the options will be exercised, and the risk free interest rate is based
on the U.S. Treasury yield in effect at the time of the grant.
Stock Warrants
--------------
On February 1, 2006, the Company and the debenture holder (See Note 3 -
Debenture Payable) mutually agreed to extend the term of the debentures until
December 1, 2007. In addition, the Company granted a warrant to purchase 400,000
shares of the Company's common stock to the debenture holder. The warrant has a
term of 2 years and is exercisable at $0.20 per share. The Company agreed to
register 3,571,429 shares of its common stock underlying the conversion of the
Debentures and the exercise of the warrant not later than 30 days after the
Company files its annual report on Form 10-KSB for the fiscal year ended
December 31, 2005. The fair value of this warrant grant was estimated at $46,686
on the date of grant using the Black-Scholes option-pricing model. In connection
with these warrants, the Company recorded debt settlement expense of $46,686.
A summary of the status of the Company's outstanding stock warrants as of June
30, 2006 and changes during the period then ended is as follows:
Number of Weighted Average
Warrants Exercise Price
--------- ----------------
Balance at December 31, 2005 ......... 9,502,500 $ 0.57
Granted .............................. 7,400,000 0.24
Exercised ............................ - -
Forfeited ............................ - -
---------- ------
Balance at June 30, 2006 ............. 16,902,500 $ 0.43
========== ======
Options exercisable at end of period . 16,902,500 $ 0.43
========== ======
Weighted average fair value of options
granted during the period ............ $ 0.24
The following information applies to all warrants outstanding at June 30, 2006:
Warrants Outstanding Warrants Exercisable
------------------------- ----------------------
Weighted
Average Weighted Weighted
Range of Remaining Average Average
Exercise Contractual Exercise Exercise
Prices Shares Life (Years) Price Shares Price
-------- --------- ------------ -------- --------- --------
$ 1.00 4,100,000 2.13 $ 1.00 4,100,000 $ 1.00
$ 0.30 4,500,000 2.75 $ 0.30 4,500,000 $ 0.30
$ 0.20 6,302,500 3.55 $ 0.20 6,302,500 $ 0.20
$ 0.25 2,000,000 1.87 $ 0.25 2,000,000 $ 0.25
-19-
TRANSAX INTERNATIONAL LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2006
(UNAUDITED)
NOTE 5 - FOREIGN OPERATIONS
The Company identifies its operating segments based on its business activities
and geographical locations. The Company operates within a single operating
segment, being a provider of information network solutions specifically designed
for healthcare providers and health insurance companies. The Company operates in
Brazil, Australia and Mauritius, and has a registered mailing address in
Singapore and in the USA. All of the Company's assets are located in Brazil.
Six months ended June 30,
2006 2005
----------- -----------
Net revenues to unaffiliated customers:
Brazil ........................ $ 2,015,902 $ 1,501,431
----------- -----------
Operating Expenses:
Brazil ........................ 1,664,023 1,216,321
USA ........................... 666,595 336,595
Australia ..................... 2,315 7,176
Mauritius ..................... 28,861 36,231
----------- -----------
2,361,794 1,596,323
----------- -----------
Loss from operations .................. (345,892) (94,892)
----------- -----------
Other income (expenses):
Brazil ........................ (203,689) (59,242)
USA ........................... (1,444,509) (119,676)
Australia ..................... - 7,950
----------- -----------
(1,648,198) (170,968)
----------- -----------
Net loss as reported .................. $(1,994,090) $ (265,860)
----------- -----------
NOTE 6 - GOING CONCERN
Since inception, the Company has incurred cumulative net losses of $12,872,724,
and at June 30, 2006 has a stockholders' deficit of $3,717,316 and has a working
capital deficit of $3,858,138. Since its inception, the Company has funded
operations through short-term borrowings and equity investments in order to meet
its strategic objectives. The Company's future operations are dependent upon
external funding and its ability to increase revenues and reduce expenses.
Management believes that sufficient funding will be available from additional
related party borrowings and private placements to meet its business objectives,
including anticipated cash needs for working capital, for a reasonable period of
time. Additionally, under the current roll out schedules with its clients, the
Company expects to increase its revenues significantly during 2006 with the
expectation of the Company becoming a profitable entity. However, there can be
no assurance that the Company will be able to obtain sufficient funds to
continue the development of its software products and distribution networks.
Furthermore, since fiscal 2000, the Company has been deficient in the payment of
Brazilian payroll taxes and Social Security taxes. At June 30, 2006, these
deficiencies (including interest and fines) amounted to approximately $815,850.
This payroll liability is included as part of the accounts payable and accrued
expenses (short-term and long-term) within the consolidated balance sheet. As a
result of the foregoing, there exists substantial doubt about the Company's
ability to continue as a going concern. These consolidated financial statements
do not include any adjustments that might result from the outcome of this
uncertainty.
NOTE 7 - SUBSEQUENT EVENT
On July 17, 2006, in connection with the conversion of $15,000 of the
convertible debenture outstanding, the Company issued 104,167 shares of common
stock.
-20-
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
This report on Form 10-QSB contains forward-looking statements that are subject
to risks and uncertainties that could cause actual results to differ materially
from those discussed in the forward-looking statements and from historical
results of operations. Among the risks and uncertainties which could cause such
a difference are those relating to our dependence upon certain key personnel,
our ability to manage our growth, our success in implementing the business
strategy, our success in arranging financing where required, and the risk of
economic and market factors affecting us or our customers. Many of such risk
factors are beyond the control of the Company and its management.
GENERAL
Transax International Limited, a Colorado corporation (the "Company"), currently
trades on the OTC Bulletin Board under the symbol "TNSX"". Transax International
Limited is referred to in this Form 10-QSB as "we".
Through our wholly-owned subsidiary Medlink Conectividade em Saude Ltda
("Medlink") (formerly TDS Telecommunication Data Systems Ltda.), we are an
international provider of health information management products (collectively,
the "Health Information Management Products"), which are specifically designed
for the healthcare providers and health insurance companies. We are dedicated to
improving healthcare delivery by providing hospitals, physician practices and
health insurance companies with innovative health information management systems
to manage coding, compliance, abstracting and record management processes. We
have developed a proprietary software trademarked (Brazil only) "MedLink
Solution", which was specifically designed and developed for the healthcare and
health insurance industry enabling the real time automation of routine patient
eligibility, verifications, authorizations, claims processing and payment
functions that were previously performed manually (the "MedLink Solution").
RESULTS OF OPERATIONS
SIX-MONTH PERIOD ENDED JUNE 30, 2006 COMPARED TO SIX-MONTH PERIOD ENDED JUNE 30,
2005
Our net losses during the six-month period ended June 30, 2006 were $1,994,090
compared to a net loss of $265,860 during the six-month period ended June 30,
2005, an increase of $1,728,230.
During the six-month period ended June 30, 2006 we generated $2,015,902 in
revenues compared to $1,501,431 in revenues for the six-month period ended June
30, 2005, an increase of $514,471 or 34.3%. The significant increase in revenues
is due to the continued installation of our software and/or hardware devices
containing our software at the healthcare providers' locations in Brazil. Upon
installation, we begin the processing of applications submitted by healthcare
providers for approval of patients for healthcare services from the insurance
carrier. We charge for these services on a per transaction basis. We undertook
approximately 3.75 million "real time" transactions during the six-month period
ended June 30, 2006 compared to 3.00 million "real time" transactions during the
period ended June 30, 2005.
During the six-month period ended June 30, 2006, we incurred operating expenses
of $2,361,794 compared to operating expenses of $1,596,323 incurred during the
six-month period ended June 30, 2005, an increase of $765,471 or 48.0%. The
increase in operating expenses during the six-month period ended June 30, 2006
from the same period in 2005 resulted from: (i) an increase of $248,440 or 43.6%
in cost of product support services resulting from the increase in revenues;
(ii) an increase of $150,621 or 200.9% in management and consulting fees-related
parties due to an increase in use of management and a director/consultant needed
to handle our increased operations; (iii) an increase of $128,964 or 34.3% in
general and administrative expenses resulting from an increase in operating
costs associated with increased operations and increased travel expenses; (iv)
an increase of $18,324 or 17.7% in depreciation and amortization expense as a
result of an increase in property and equipment acquired for our Medlink
operations; (v) an increase of $127,764 in investor relations fees primarily
resulting from the issuance of common stock and warrants to a consultant for
investor relations services; (vi) an increase of $44,401 or 62.4% in
-21-
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (CONTINUED)
professional fees relating to legal and accounting costs associated with our
financings and the filing of a registration statement on Form SB-2 and (vii) an
increase of $46,957 or 12.2% in compensation and related benefits associated
with the increased operations at our Medlink operations.
We reported a loss from operations of $345,892 for the six-month period ended
June 30, 2006 as compared to a loss from operations of $94,892 for the six-month
period ended June 30, 2005, an increase of $251,000. Although there can be no
assurances, we anticipate that during fiscal year 2006, our ongoing marketing
efforts and product roll-out will result in an increase in our net sales from
those reported during fiscal year 2005. To support these increased sales, we
anticipate that our operating expenses will also increase during fiscal year
2006 as compared to fiscal year 2005. We are, however, unable to predict at this
time the amount of any such increase in operating expenses.
Total other expenses increased $1,477,230 or 864.0% for the six-month period
ended June 30, 2006 as compared to the six-month period ended June 30, 2005.
Included in this change is: (i) an increase in other expense of $58,989 from
$10,514 of other income recognized during the six-month period ended June 30,
2005; (ii) an increase of $153,671 in debt settlement and offering costs from
$-0- during the six-month period ended June 30, 2005, which relates to the
issuance of warrants to the debenture holder and amortization of certain debt
offering costs; (iii) an increase of $1,168,930 in loss from derivative
liabilities from $15,804 during the six-month period ended June 30, 2005, which
relates to the classification of the embedded conversion feature and related
warrants issued in connection with our Series A preferred stock and debenture
payable as a derivative instrument; and (iv) an increase of $59,738 in interest
expense from $192,112 for the six-month period ended June 30, 2005, which
reflects an increase in our borrowings during the six-month period ended June
30, 2006 and the amortization of debt discounts and debt offering costs of
$72,066.
For the six-month period ended June 30, 2006 our net loss was $1,994,090
compared to a net loss of $265,860 for the six-month period ended June 30, 2005.
During the six months ended June 30, 2006, we recorded a deemed preferred stock
dividend of $1,600,000 which relates to our Series A Convertible Preferred
Stock. This non-cash item related to the embedded beneficial conversion features
of those securities and fair value of warrants of those securities. Additional,
for the six months ended June 30, 2006, we recorded cumulative preferred stock
dividends of $34,214.
We reported a net loss attributable to common shareholders of $3,628,304 for the
six months ended June 30, 2006 as compared to a net loss attributable to common
shareholders of $265,860 for the six months ended June 30, 2005. This translates
to an overall per-share loss available to shareholders of ($0.06) and ($0.01)
for the six months ended June 30, 2006 and 2005, respectively.
THREE-MONTH PERIOD ENDED JUNE 30, 2006 COMPARED TO THREE-MONTH PERIOD ENDED JUNE
30, 2005
Our net losses during the three-month period ended June 30, 2006 were $1,302,259
compared to a net loss of $167,041 during the three-month period ended June 30,
2005, an increase of $1,135,218.
During the three-month period ended June 30, 2006 we generated $1,034,844 in
revenues compared to $861,023 in revenues for the three-month period ended June
30, 2005, an increase of $173,821 or 20.2%. The significant increase in revenues
is due to the continued installation of our software and/or hardware devices
containing our software at the healthcare provider's locations in Brazil. Upon
installation, we begin the processing of applications submitted by the
healthcare provider for approval of patients for healthcare services from the
insurance carrier. We charge for these services on a per transaction basis. We
undertook approximately 1.84 million "real time" transactions during the
three-month period ended June 30, 2006 compared to 1.33 million "real time"
transactions during the period ended June 30, 2005.
-22-
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (CONTINUED)
During the three-month period ended June 30, 2006, we incurred operating
expenses of $1,258,835 compared to operating expenses of $916,787 incurred
during the three-month period ended June 30, 2005, an increase of $342,048 or
37.3%. The increase in operating expenses during the three-month period ended
June 30, 2006 from the same period in 2005 resulted from: (i) an increase of
$71,284 or 20.0% in cost of product support services resulting from the increase
in revenues; (ii) an increase of $75,495 or 183.0% in management and consulting
fee-related parties due to an increase in use of management and a
director/consultant needed to handle our increased operations; (iii) an increase
of $88,296 or 47.6% in general and administrative expenses resulting from a
increase in operating costs associated with increased operations and increased
travel expenses; (iv) a decrease of $2,812 or 4.8% in depreciation and
amortization expense; (v) an increase of $118,247 in investor relations fees
primarily resulting from the issuance of common stock and warrants to a
consultant for investor relations services; (vi) a decrease of $13,154 or 22.3%
in professional fees relating to certain accounting costs incurred in 2005; and
(vii) an increase of $4,692 or 2.2% in compensation and related benefits
associated with the increased operations at our Medlink operations.
We reported a loss from operations of $223,991 for the three-month period ended
June 30, 2006 as compared to a loss from operations of $55,764 for the
three-month period ended June 30, 2005, an increase of $168,227. Although there
can be no assurances, we anticipate that during fiscal year 2006, our ongoing
marketing efforts and product roll-out will result in an increase in our net
sales from those reported during fiscal year 2005. To support these increased
sales, we anticipate that our operating expenses will also increase during
fiscal year 2006 as compared to fiscal year 2005. We are, however, unable to
predict at this time the amount of any such increase in operating expenses.
Total other expenses increased $966,991 or 869.0% for the three-month period
ended June 30, 2006 as compared to the six-month period ended June 30, 2005.
Included in this change is: (i) an increase in other expense of $26,126 from $0
of other expenses recognized during the three-month period ended June 30, 2005;
(ii) an increase of $919,827 in loss from derivative liabilities from $15,804
during the three-month period ended June 30, 2005, which relates to the
classification of the embedded conversion feature and related warrants issued in
connection with our Series A preferred stock and debenture payable as a
derivative instrument; and (iii) a decrease of $9,487 in interest expense from
$119,405 for the three-month period ended June 30, 2005, which reflects an
increase in our borrowings and the amortization of debt discounts and debt
offering costs of $36,033 during the three-month period ended June 30, 2006
offset by the recording of interest expense of $31,200 and $31,250 during the
three months ended June 30, 2005 related to the granting of warrants and the
recording of a beneficial conversion feature, respectively.
For the three-month period ended June 30, 2006 our net loss was $1,302,259
compared to a net loss of $167,041 for the three-month period ended June 30,
2005.
During the three months ended June 30, 2006, we recorded a deemed preferred
stock dividend of $800,000 which is related to our Series A Convertible
Preferred Stock. This non-cash expense related to the embedded beneficial
conversion features of those securities and fair value of warrants of those
securities. Additionally, for the three months ended June 30, 2006, we recorded
cumulative preferred stock dividends of $34,214.
We reported a net loss attributable to common shareholders of $2,136,473 for the
three months ended June 30, 2006 as compared to a net loss attributable to
common shareholders of $167,041 for the three months ended June 30, 2005. This
translates to an overall per-share loss available to shareholders of ($0.04) and
($0.01) for the three months ended June 30, 2006 and 2005, respectively.
LIQUIDITY AND CAPITAL RESOURCES
As of June 30, 2006, our current assets were $1,085,530 and our current
liabilities were $4,943,668, which resulted in a working capital deficit of
$3,858,138. As of June 30, 2006, our total assets were $2,196,551 consisting of:
(i) $482,813 in cash; (ii) $202,893 in prepaid expenses and other current
assets; (iii) $399,824 in accounts receivable; (iv) $358,514 in net software
development costs; (v) $733,359 in net property and equipment; (vi) $4,800 in
other assets; and (vii) $14,348 in deferred debt offering costs.
-23-
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (CONTINUED)
As of June 30, 2006, our total liabilities were $5,913,867 consisting of: (i)
$1,774,974 in long-term and current portion of accounts payable and accrued
expenses; (ii) $229,766 due to related parties; (iii) $207,035 in convertible
loans to related parties; (iv) $147,791 in loan payable to related parties; (v)
$156,250 in net convertible debenture payable; (vi) $298,119 in loans payable;
(vii) $1,000,783 in warrant liability; and (viii) $2,099,149 in convertible
feature liability. As at June 30, 2006, our current liabilities were $4,943,668
compared to $2,563,200 at December 31, 2005. The increase in current liabilities
is due primarily to the recording of warrant and convertible feature liabilities
offset by the repayment of loans and related loans payable.
Stockholders' deficit increased from $1,627,640 for fiscal year ended December
31, 2005 to $3,717,316 for the six-month period ended June 30, 2006.
For the six-month period ended June 30, 2006, net cash flow used in operating
activities was $310,974 compared to net cash provided by operating activities of
$251,045 for the six-month period ended June 30, 2005. The change in cash flows
used by operating activities is due to the increase in net loss for the
six-month period ended June 30, 2006 as well as the repayment of accounts
payable.
Net cash flows used in investing activities amounted to $344,813 for the
six-month period ended June 30, 2006 compared to $484,404 for the six-month
period ended June 30, 2005, a decrease of $139,591. During the six-month period
ended June 30, 2006, we capitalized software development costs and acquired
equipment for our hardware and software installations while in the six-month
period ended June 30, 2005, these costs were higher.
Net cash flows provided by financing activities for the six-month period ended
June 30, 2006 were $1,129,059, resulting primarily from net proceeds from the
sale of shares of Series A Preferred Stock of $1,223,734 and proceeds from loans
in the amount of $6,614 offset by repayment of capital lease obligations of
$16,289 and the repayment of related party loans of $85,000. Net cash flows
provided by financing activities were $407,674 for the six-month period ended
June 30, 2005 resulting from proceeds from a convertible debenture of $336,738,
proceeds from loans payable of $141,982 offset by repayment of related party
advances of $35,000, repayment of capital lease obligations of $20,962 and the
repayment of related party loans of $15,084.
In summary, based upon the cash flow activities as previously discussed, for the
six-month period ended June 30, 2006, our overall cash position increased by
$474,939.
PLAN OF OPERATION
Since our inception, we have funded operations through short-term borrowings and
equity investments in order to meet our strategic objectives. Our future
operations are dependent upon external funding and our ability to increase
revenues and reduce expenses. Management believes that sufficient funding will
be available from additional related party borrowings and private placements to
meet our business objectives including anticipated cash needs for working
capital, for a reasonable period of time. However, there can be no assurance
that we will be able to obtain sufficient funds to continue the development of
our software products and distribution networks.
On January 13, 2006, we entered into an Investment Agreement with Cornell
Capital Partners ("Cornell") (the "Parties"), pursuant to which we sold to
Cornell 16,000 shares of Series A Convertible Preferred Stock, no par value per
share, (the "Series A Preferred Shares") which shall be convertible, at
Cornell's discretion, into shares of our common stock, par value $.00001 per
share (the "Common Stock") for a total price of up to $1,600,000.
Of the 16,000 Series A Preferred Shares to be sold to Cornell, 8,000 Series A
Preferred Shares had a purchase price of $800,000, which consisted of $255,237
from the surrender of a Promissory Note (as described below) and $544,763 in new
funding, of which we received net proceeds of $470,734 after the payment of
placement fees and expenses of $74,029. On May 8, 2006, we sold the remaining
8,000 shares of Series A Preferred Shares to Cornell, for the purchase price of
$800,000 and received net proceeds of $728,000 (net of placement fees of
$72,000).
-24-
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (CONTINUED)
Certain negative covenants in the Investment Agreement could substantially
impact our ability to raise funds from alternative sources in the future. For
example, so long as any Series A Preferred Shares are outstanding, we shall not,
without the prior written consent of Cornell Capital Partners: (a) directly or
indirectly consummate any merger, reorganization, restructuring, reverse stock
split consolidation, sale of all or substantially all of our assets or any
similar transaction or related transactions; (b) incur any indebtedness for
borrowed money or become a guarantor or otherwise contingently liable for any
such indebtedness except for trade payables or purchase money obligations
incurred in the ordinary course of business; (c) file any other registration
statements on any form (including but not limited to forms S-1, SB-2, S-3 and
S-8); (d) issue or sell shares of common stock or preferred stock without
consideration or for a consideration per share less than the bid price of the
common stock determined immediately prior to its issuance or issue any preferred
stock, warrant, option, right, contract, call, or other security or instrument
granting the holder thereof the right to acquire common stock without
consideration or for a consideration per share less than the bid price of the
common stock determined immediately prior to the issuance of such convertible
security; or (e) enter into any security instrument granting the holder a
security interest in any and all of our assets.
In connection with the sale of the Series A Preferred Shares, on January 13,
2006, the Parties agreed that Cornell would surrender the Promissory Note issued
by us to them on May 17, 2005, in the principal amount of $255,237, in exchange
for $255,237 of Series A Preferred Shares. As of January 13, 2006, the full
amount outstanding under the Promissory Note was $255,237, plus accrued and
unpaid interest of $0. As a result of the Parties' agreement, the Promissory
Note was retired and canceled. The Parties also agreed to terminate the
Securities Purchase Agreement and the Investor Registration Rights Agreement,
each dated as of October 25, 2004, as well as the Pledge and Escrow Agreements,
each dated October 21, 2004, that were entered into by the Parties in connection
with the issuance of the Promissory Note.
On January 13, 2006, we also issued to Cornell warrants to purchase up to
5,000,000 shares of Common stock. The first warrant issued to Cornell, for
2,500,000 shares of Common Stock at an exercise price of $0.30 per share, shall
terminate after the five (5) year anniversary of the date of issuance. The
second warrant issued to Cornell was for 2,500,000 shares of Common Stock at an
exercise price of $0.20 per share, and shall terminate after the five (5) year
anniversary of the date of issuance.
As of the date of this Quarterly Report, there is substantial doubt regarding
our ability to continue as a going concern as we have not generated sufficient
cash flow to fund our business operations and material commitments. Our future
success and viability, therefore, are dependent upon our ability to develop,
provide and market our information network solutions to healthcare providers,
health insurance companies and other end-users, and the continuing ability to
generate capital financing. We are optimistic that we will be successful in our
business operations and capital raising efforts; however, there can be no
assurance that we will be successful in generating revenue or raising additional
capital. The failure to generate sufficient revenues or raise additional capital
may have a material and adverse effect upon us and our shareholders.
We anticipate an increase in operating expenses over the next three years to pay
costs associated with such business operations. We may need to raise additional
funds. We may finance these expenses with further issuances of our common stock.
We believe that any anticipated private placements of equity capital and debt
financing, if successful, may be adequate to fund our operations over the next
twelve months. Thereafter, we expect we will need to raise additional capital to
meet long-term operating requirements. If we raise additional funds through the
issuance of equity or convertible debt securities other than to current
shareholders, the percentage ownership of our current shareholders would be
reduced, and such securities might have rights, preferences or privileges senior
to our existing common stock. In addition, additional financing may not be
available upon acceptable terms, or at all. If adequate funds are not available,
or are not available with acceptable terms, we may not be able to conduct our
business operations successfully. This eventuality could significantly and
materially restrict our overall business operations.
-25-
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (CONTINUED)
Based upon a twelve-month work plan proposed by management, it is anticipated
that such a work plan would require approximately $1,000,000 to $3,000,000 of
financing designed to fund various commitments and business operations.
In April 2005, we entered into a Securities Purchase Agreement with Scott and
Heather Grimes, Joint Tenants with Right of Survivorship (the "Investor"). Under
the terms of the Securities Purchase Agreement with the Investor, we issued
convertible debentures to the Investor in the original principal amount of
$250,000. The debentures are convertible at the Investor's option any time up to
maturity at a conversion price equal to the lower of: (i) 120% of the closing
bid price of our common stock on the date of the debentures, or (ii) 80% of the
lowest closing bid price of our common stock for the five trading days
immediately preceding the conversion date. The debentures have a two-year term
and accrue interest at 5% per year. At maturity, the debentures will
automatically convert into shares of our common stock at a conversion price
equal to the lower of: (i) 120% of the closing bid price of our common stock on
the date of the debentures, or (ii) 80% of the lowest closing bid price on our
common stock for five trading days immediately preceding the conversion date.
On February 1, 2006, we and the debenture holder mutually agreed to extend the
term of the debentures until December 1, 2007. In addition, we granted a warrant
to purchase 400,000 shares of our common stock to the debenture holder. The
warrant has a term of 2 years and is exercisable at $0.20 per share. We agreed
to register 3,571,429 shares of our common stock underlying the conversion of
the Debentures and the exercise of the warrant on a best efforts basis not later
than 30 days after we filed our Annual Report on Form 10-KSB for the fiscal year
ended December 31, 2005. On May 9, 2006 a registration statement was filed with
the Securities and Exchange Commission.
Certain negative covenants in the Securities Purchase Agreement could
substantially impact our ability to raise funds from alternative sources in the
future. For example, for as long as the convertible debenture remains
outstanding and without the written consent of the debenture holder, the Company
(a) shall not directly or indirectly consummate any merger, reorganization,
restructuring, reverse stock split consolidation, sale of all or substantially
all of the Company's assets or any similar transaction or related transactions;
(b) shall not issue or sell shares of common stock or preferred stock without
consideration or for a consideration per share less than the bid price of the
common stock determined immediately prior to its issuance or issue any warrant,
option, right, contract, call, or other security or instrument granting the
holder thereof the right to acquire common stock without consideration or for a
consideration per share less than the bid price of the common stock determined
immediately prior to the issuance of such convertible security; (c) shall not
enter into any security instrument granting the holder a security interest in
any or all assets of the Company; (d) shall not file any registration statement
on Form S-8 except the Company may file one registration statement on Form S-8
for up to 2,500,000 shares of common stock and provided however, anyone
receiving shares pursuant to such permitted Form S-8 registration shall be
restricted from selling such shares for a period of ninety (90) days after the
registration statement becomes effective and (e) shall not, and shall cause each
of its subsidiaries not to, enter into, amend, modify or supplement, or permit
any subsidiary to enter into, amend, modify or supplement any agreement,
transaction, commitment, or arrangement with any of its or any of its
subsidiary's officers, directors, person who were officers or directors at any
time during the previous two years, stockholders who beneficially own five
percent (5%) or more of the Company's common stock, or Affiliates (as defined in
the Securities Purchase Agreement) or with any individual related by blood,
marriage, or adoption to any such individual or with any entity in which any
such entity or individual owns a five percent (5%) or more beneficial interest,
except for (i) customary employment arrangements and benefit programs on
reasonable terms, (ii) any investment in an Affiliate of the Company, (iii) any
agreement, transaction, commitment, or arrangement on an arms-length basis on
terms no less favorable than terms which would have been obtainable from a
person other than such related party and (iv) any agreement transaction,
commitment, or arrangement which is approved by a majority of the disinterested
directors of the Company.
-26-
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (CONTINUED)
We believe that we can satisfy our cash requirements for the next twelve months
based on our ability to enter into additional financing arrangements as
necessary. Our future success and viability are primarily dependent upon our
current management to generate revenues from business operations and raise
additional capital through further private offerings of our stock or loans from
private investors. There can be no assurance, however, that we will be able to
raise additional capital. Our failure to successfully raise additional capital
will have a material and adverse affect upon us and our shareholders.
MATERIAL COMMITMENTS
CONVERTIBLE LOANS - RELATED PARTY
A significant material liability for us for fiscal year 2006 is the aggregate
principal amount of $175,000 and $32,035 in accrued interest due and owing to a
related party in accordance with two convertible promissory notes (collectively,
the "Convertible Promissory Note(s)"). Previously, the aggregate principal
amounts of the Convertible Promissory Notes were $200,000 and $100,000,
respectively. During March 2005, we modified the terms of the Convertible
Promissory Notes: (i) $200,000 is due on March 31, 2007 and convertible into
shares of our common stock at $0.125 per share together with a warrant per share
to purchase our common stock at $0.25 per share for a period of two years; and
(ii) $100,000 is due on April 30, 2007 and convertible into shares of our common
stock at $0.125 per shares together with a warrant per share to purchase our
common stock at $0.25 per share for a period of two years. On June 28, 2005 and
September 30, 2005, the holders of the Convertible Promissory Notes partially
exercised the respective conversion rights. As at June 30, 2006, an aggregate
principal amount of $175,000 and interest in the amount of $32,035 remains due
and owing under the Convertible Promissory Notes.
LOAN - RELATED PARTY
A significant material liability for us for fiscal year 2006 is the aggregate
amount of $144,336 in principal due and owing to a related party (the "Loan").
The $144,336 Loan is evidenced by a promissory note with an interest rate of
0.8% per month compounded and was repayable during March 2006. As of the date of
this Quarterly Report, the Loan due date is being negotiated. Additionally,
during 2005, we borrowed $85,000 from this officer, which amount was repaid
during the six-month period ended June 30, 2006. At June 30, 2006, $3,455 in
interest was accrued on this loan.
-27-
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (CONTINUED)
CONSULTING AGREEMENT
A significant and estimated material liability for us for fiscal year 2006 is
the aggregate amount of $209,869 due and owing to Stephen Walters, our
President. In accordance with the terms of an agreement, effective April 2006,
we pay monthly to Mr. Walters an aggregate amount of $15,000 as compensation for
managerial and consulting services he provides.
CONVERTIBLE DEBENTURE
A significant material liability for us for fiscal year 2006 is the convertible
debenture payable in the amount of $250,000. On April 1, 2005, we entered into a
financing agreement with Scott and Heather Grimes, Joint Tenants with Right of
Survivorship (the "Investor"). Under the terms of the financing arrangement with
the Investor, we issued convertible debentures to the Investor in the original
principal amount of $250,000. The debentures are convertible at the Investor's
option any time up to maturity at a conversion price equal to the lower of: (i)
120% of the closing bid price of our common stock on the date of the debentures,
or (ii) 80% of the lowest closing bid price of our common stock for the five
trading days immediately preceding the conversion date. The debentures have a
two-year term and accrue interest at 5% per year. At maturity, the debentures
will automatically convert into shares of our common stock at a conversion price
equal to the lower of: (i) 120% of the closing bid price of our common stock on
the date of the debentures, or (ii) 80% of the lowest closing bid price on our
common stock for five trading days immediately preceding the conversion date. On
February 1, 2006 we agreed to extend the term of the debentures to December 1,
2007 and issued 400,000 warrants at 0.20 per share valid for two years.
ACCRUED TAXES AND RELATED EXPENSES
A significant and estimated material liability for us for fiscal year 2006 is
the aggregate amount of approximately $816,000 due and owing for Brazilian
payroll taxes and Social Security taxes.
Effective April 1, 2004, we entered into a payment program with the Brazilian
authorities whereby the Social Security ("INSS") taxes due and applicable
penalties and interests will be repaid over a period of up to 60 months. We made
the first payment as per the plan in April 2004 and have continued to make the
required payments. At June 30, 2006, approximately $263,000 of our INSS taxes is
to be repaid over periods from 20-50 months. The payment program requires us to
pay a monthly fixed amount of approximately $9,000. During February 2006, we
entered into a payment program for $30,000 of other taxes to be repaid over a
period of 60 months. During July 2006, we repaid $188,348 of Income and
Withholding taxes for prior years.
CRITICAL ACCOUNTING POLICIES
Our financial statements and accompanying notes are prepared in accordance with
generally accepted accounting principles in the United States. Preparing
financial statements requires management to make estimates and assumptions that
affect the reported amounts of assets, liabilities, revenue and expenses. These
estimates and assumptions are affected by management's applications of
accounting policies. Critical accounting policies for Transax International
Limited include the useful lives of property and equipment and accounting for
stock based compensation.
We review the carrying value of property and equipment for impairment at least
annually or whenever events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable. Recoverability of long-lived
assets is measured by the comparison of its carrying amount to the undiscounted
cash flows that the asset or asset group is expected to generate. If such assets
are considered to be impaired, the impairment to be recognized is measured by
the amount by which the carrying amount of the property, if any, exceeds its
fair market value.
-28-
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (CONTINUED)
Under the criteria set forth in SFAS No. 86, "Accounting for the Costs of
Computer Software to be Sold, Leased or Otherwise Marketed", capitalization of
software development costs begins upon the establishment of technological
feasibility of the software. The establishment of technological feasibility and
the ongoing assessment of the recoverability of these costs require considerable
judgment by management with respect to certain external factors, including, but
not limited to, anticipated future gross product revenues, estimated economic
life, and changes in software and hardware technology. Capitalized software
development costs are amortized utilizing the straight-line method over the
estimated economic life of the software not to exceed three years. We regularly
review the carrying value of software development assets and a loss is
recognized when the unamortized costs are deemed unrecoverable based on the
estimated cash flows to be generated from the applicable software.
Accounting for Stock Based Compensation - Effective January 1, 2006, we adopted
Statement of Financial Accounting Standards No. 123 (revised 2004), Share Based
Payment ("SFAS No. 123R"). SFAS No. 123R establishes the financial accounting
and reporting standards for stock-based compensation plans. As required by SFAS
No. 123R, we recognize the cost resulting from all stock-based payment
transactions including shares issued under its stock option plans in the
financial statements. The adoption of this pronouncement may have a material
effect on our results of operations.
Revenue Recognition - Our revenues, which do not require any significant
production, modification or customization for the Company's targeted customers
and do not have multiple elements, is recognized when (1) persuasive evidence of
an arrangement exists; (2) delivery has occurred; (3) the Company's fee is fixed
and determinable, and; (4) collectibility is probable.
Substantially all of our revenues are derived from the processing of
applications by healthcare providers for approval of patients for healthcare
services from insurance carriers. Our software or hardware devices containing
our software are installed at the healthcare provider's location. We offer
transaction services to authorize and adjudicate identity of the patient and
obtain "real time" approval for any necessary medical procedure from the
insurance carrier. Our transaction-based solutions provide remote access for
healthcare providers to connect with contracted insurance carriers. Transaction
services are provided through contracts with insurance carriers and others,
which specify the services to be utilized and the markets to be served. Our
clients are charged for these services on a per transaction basis. Pricing
varies depending on the type of transactions being processed under the terms of
the contract for which services are provided. Transaction revenues are
recognized in the period in which the transactions are performed.
OFF BALANCE SHEET ARRANGEMENTS
As of the date of this Quarterly Report, we do not have any off-balance sheet
arrangements that have or are reasonably likely to have a current or future
effect on our financial condition, changes in financial condition, revenues or
expenses, results of operations, liquidity, capital expenditures or capital
resources that are material to investors. The term "off-balance sheet
arrangement" generally means any transaction, agreement or other contractual
arrangement to which an entity unconsolidated with us is a party, under which we
have: (i) any obligation arising under a guarantee contract, derivative
instrument or variable interest; or (ii) a retained or contingent interest in
assets transferred to such entity or similar arrangement that serves as credit,
liquidity or market risk support for such assets.
-29-
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (CONTINUED)
RECENT ACCOUNTING PRONOUNCEMENTS
In February 2006, the FASB issued SFAS No. 155, "Accounting for Certain Hybrid
Financial Instruments - an amendment of FASB Statements No. 133 and 140" ("SFAS
155"). SFAS 155 permits fair value re-measurement for any hybrid financial
instrument that contains an embedded derivative that otherwise would require
bifurcation and clarifies which interest-only strips and principal-only strips
are not subject to the requirements of Statement 133. FAS 155 establishes a
requirement to evaluate interests in securitized financial assets to identify
interests that are freestanding derivatives or that are hybrid financial
instruments that contain an embedded derivative requiring bifurcation and
clarifies that concentrations of credit risk in the form of subordination are
not embedded derivatives. Lastly, SFAS 155 amends SFAS 140 to eliminate the
prohibition on a qualifying special-purpose entity from holding a derivative
financial instrument that pertains to a beneficial interest other than another
derivative financial instrument. SFAS 155 is effective in the first fiscal year
that begins after September 15, 2006. We are still assessing the impact, if any,
on its consolidated financial position, results of operations and cash flows.
ITEM 3. CONTROLS AND PROCEDURES
We maintain "disclosure controls and procedures," as such term is defined in
Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act"),
that are designed to ensure that information required to be disclosed in our
Exchange Act reports is recorded, processed, summarized and reported within the
time periods specified in the Securities and Exchange Commission rules and
forms, and that such information is accumulated and communicated to our
management, including our Chief Executive Officer and Chief Financial Officer,
as appropriate, to allow timely decisions regarding required disclosure. We
conducted an evaluation (the "Evaluation"), under the supervision and with the
participation of our Chief Executive Officer ("CEO") and Chief Financial Officer
("CFO"), of the effectiveness of the design and operation of our disclosure
controls and procedures ("Disclosure Controls") as of the end of the period
covered by this report pursuant to Rule 13a-15 of the Exchange Act.
Our management, including our CEO and CFO, do not expect that our disclosure
controls and internal controls will prevent all errors and all fraud. A control
system, no matter how well conceived and operated, can provide only reasonable,
not absolute, assurance that the objectives of the control system are met. Our
disclosure controls and procedures are designed to provide reasonable assurance
of achieving our objectives.Our certifying officers have concluded that our
disclosure controls and procedures were ineffective as at June 30, 2006.
However, the design of a control system must reflect the fact that there are
resource constraints, and the benefits of controls must be considered relative
to their costs. It is our responsibility and that of our management to identify
any deficiencies in internal controls over financial reporting. We discovered
certain deficiencies in our internal control over financial reports, which
resulted in the restatement of our financial statements as discussed below. The
restatement was undertaken to properly reflect an embedded derivative conversion
liability related to our debentures payable in accordance with SFAS No. 133 and
EITF 00-19 after further consultation with our independent auditors.
We have implemented additional measures as part of changes to our internal
controls to determine and ensure that information required to be disclosed in
reports filed under the exchange Act was recorded, processed, summarized and
reported within the time periods specified in the rules and forms including, but
not limited to, the following: (i) documentation of processes, performing
testing and reviewing our internal control over financial reporting in
connection with our assessment under Section 404 of the Sarbanes-Oxley Act
(although we are not currently subject to Section 404 and, as a consequence,
neither management nor our auditors have examined or rendered a report
concerning the effectiveness of our internal controls over financial reporting,
and we undertake this assessment in preparation for the assessment we would be
-30-
ITEM 3. CONTROLS AND PROCEDURES (CONTINUED)
making at a later time when we become subject to the requirements of Section
404); (ii) evaluation and implementation of improvements to our accounting and
management information systems; and (iii) development and implementation of a
remediation plan to address any perceived deficiencies identified in our
internal control over financial reporting. The costs of these additional
measures did not have a material impact on our future results or operations
liquidity.
On July 6, 2006, we announced that we were restating our Consolidated Financial
Statements at June 30, 2005, September 30, 2005, December 31, 2005 and March 31,
2006 to properly reflect an embedded derivative conversion liability related to
our debenture payable in accordance with SFAS No. 133 and EITF 00-19. The change
in presentation of the Company's embedded derivative feature associated with its
debenture payable had the effect of increasing assets by $19,131, increasing
liabilities by $208,117, increasing the stockholders' deficit by $188,986 as of
March 31, 2006, and increasing the Company's net loss by $30,038 for the three
months ended March 31, 2006. This change in presentation of the Company's
embedded derivative feature affected some of the items within the Company's
consolidated statement of cash flows for the three months ended March 31, 2006
but did not impact cash at the end of the year.
Our certifying officers have concluded that our disclosure controls and
procedures were ineffective as at June 30, 2006 related to the presentation of
derivative liabilities. However, we believe that the implementation of changes
to our internal controls and procedures as detailed above has corrected this
deficiency.
Other than the changes related to the proper presentation and recording of
derivative liabilities, there were no changes during our last fiscal quarter in
the Company's internal control over financial reporting identified in connection
with the evaluation required by paragraph (d) of Rule 13a-15 under the Exchange
Act with respect to the period ended March 31, 2006 that have materially
affected, or are reasonably likely to materially affect, the Company's internal
control over financial reporting.
Because of the inherent limitations in all control systems, no evaluation of
controls can provide absolute assurance that all control issues and instances of
fraud, if any, within the Company have been detected. These inherent limitations
include the realities that judgments in decision-making can be faulty, and that
breakdowns can occur because of a simple error or mistake. Additionally,
controls can be circumvented by the individual acts of some persons, by
collusion of two or more people, or by management or board override of the
controls. The design of any system of controls also is based in part upon
certain assumptions about the likelihood of future events, and there can be no
assurance that any design will succeed in achieving its stated goals under all
potential future conditions; over time, controls may become inadequate because
of changes in conditions, or the degree of compliance with the policies or
procedures may deteriorate. Because of the inherent limitations in a
cost-effective control system, misstatements due to error or fraud may occur and
not be detected.
-31-
PART II - OTHER INFORMATION
Item 1 - Legal Proceedings
On March 14, 2005, X-Clearing Corp, a Colorado corporation
("X-Clearing"), our former transfer agent, initiated legal proceedings
against us by filing a complaint and verified motion for replevin and
for temporary order to preserve property in the District Court of the
City and County of Denver, State of Colorado, civil action no. 05 CV
1980 (the "Complaint").
On August 9, 2006, we entered into a Settlement Agreement with
X-Clearing releasing all claims and counterclaims of the complaint
without any admission of liability for an out of court settlement of
$37,250.
Other than as disclosed above, we are not aware of any legal
proceedings contemplated by any governmental authority or other party
involving us or our subsidiaries or our properties. None of our
directors, officers or affiliates are: (i) a party adverse to us in any
legal proceedings; or (ii) has an adverse interest to us in any legal
proceedings. We are not aware of any other legal proceedings pending or
that have been threatened against us, our subsidiaries or our
properties.
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds
Cornell Capital Partners
On January 13, 2006, in accordance with the terms and provisions of the
2006 Investment Agreement, we issued to Cornell: (i) 8,000 shares of
Series A Convertible Preferred for aggregate consideration of $800,000,
which consisted of $255,237 from the surrender of the Cornell Capital
Promissory Note and $544,763 in cash from which we received net
proceeds of $470,734 after the payment of placement fees and expenses
of $74,029; (ii) five-year warrant exercisable into 2,500,000 shares of
our common stock at an exercise price of $0.30; and (iii) a five-year
warrant exercisable into 2,500,000 shares of our common stock at an
exercise price of $0.20.
On May 8, 2006, in accordance with the terms and provisions of the 2006
Investment Agreement, we issued to Cornell a further 8,000,000 shares
of Series A Convertible Preferred for aggregate consideration of
$800,000, of which we received net proceeds of $728,000 after the
payment of placement fees and expenses.
We were required to prepare and file a registration statement under the
Securities Act of 1933, as amended, for registration of the resale of
the underlying common stock and warrants, including at least 25,000,000
shares underlying the Series A Convertible Preferred and 5,000,000
Warrant shares. We filed our initial registration statement on Form
SB-2 on May 9, 2006.
-32-
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds (continued)
ROI Group Associates Inc.
On March 20, 2006, we entered into a one-year consulting contract for
business development services with ROI Group Associates Inc. In
connection with the agreement, we agreed to issue 900,000 shares of
common stock. We valued these common shares at the fair market value on
the dates of grant or $0.12 per share based on the quoted trading price
and recorded deferred consulting expense of $108,000 to be amortized
over the service period. In addition, we granted a warrant to purchase
2,000,000 shares of the Company's common stock. The warrant has a term
expiring January 31, 2009. 1,000,000 of the warrants are exercisable at
$0.20 per share and 1,000,000 of the warrants are exercisable at $0.25
per share. As of March 31, 2006 these shares had not been issued and
are included in common stock issuable on the accompanying balance
sheet.
Item 3 - Defaults Upon Senior Securities
None
Item 4 - Submissions of Matters to a Vote of Security Holders
None
Item 5 - Other Information
None
Item 6 - Exhibits
31.1 Certification of the Chief Executive Officer pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002
31.2 Certification of the Chief Financial Officer pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002
32.1 Certification of Chief Executive Officer Certification pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
32.2 Certification of Chief Financial Officer Certification pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
TRANSAX INTERNATIONAL LIMITED
Date: October 13, 2006 By: /s/ Stephen Walters
-------------------
Stephen Walters
Chief Executive Officer
Date: October 13, 2006 By: /s/ Adam Wasserman
------------------
Adam Wasserman
Principal Financial and
Accounting Officer
-33-